Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by AbbVie
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01412021
First received: August 5, 2011
Last updated: April 7, 2017
Last verified: April 2017

August 5, 2011
April 7, 2017
August 2011
June 2018   (Final data collection date for primary outcome measure)
  • Number of patients with adverse drug reactions [ Time Frame: at week 24 ]
    Occurrence of adverse event (yes or no), nature of adverse drug reactions, date of onset, seriousness, clinical course of adverse drug reactions, outcome, measures, causal relationship between the adverse drug reactions and Humira
  • Disease Activity Score28 [ Time Frame: at week 4 ]
  • Disease Activity Score28 [ Time Frame: at week 8 ]
  • Disease Activity Score28 [ Time Frame: at week 12 ]
  • Disease Activity Score28 [ Time Frame: at week 16 ]
  • Disease Activity Score28 [ Time Frame: at week 24 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 4 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 8 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 12 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 16 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 24 ]
  • Height [ Time Frame: at week 4 ]
  • Height [ Time Frame: at week 8 ]
  • Height [ Time Frame: at week 12 ]
  • Height [ Time Frame: at week 16 ]
  • Height [ Time Frame: at week 24 ]
  • Weight [ Time Frame: at week 4 ]
  • Weight [ Time Frame: at week 8 ]
  • Weight [ Time Frame: at week 12 ]
  • Weight [ Time Frame: at week 16 ]
  • Weight [ Time Frame: at week 24 ]
  • Anti-cyclic citrullinated peptides antibodies [ Time Frame: at baseline ]
  • Anti-cyclic citrullinated peptides antibodies [ Time Frame: at week 24 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 4 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 8 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 12 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 16 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 24 ]
  • Number of patients with adverse drug reactions [ Time Frame: at week 24 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira
  • Disease Activity Score28 [ Time Frame: at week 4 ]
  • Disease Activity Score28 [ Time Frame: at week 8 ]
  • Disease Activity Score28 [ Time Frame: at week 12 ]
  • Disease Activity Score28 [ Time Frame: at week 16 ]
  • Disease Activity Score28 [ Time Frame: at week 24 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 4 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 8 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 12 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 16 ]
  • Serum Matrix metalloprotease-3 level [ Time Frame: at week 24 ]
  • Height [ Time Frame: at week 4 ]
  • Height [ Time Frame: at week 8 ]
  • Height [ Time Frame: at week 12 ]
  • Height [ Time Frame: at week 16 ]
  • Height [ Time Frame: at week 24 ]
  • Weight [ Time Frame: at week 4 ]
  • Weight [ Time Frame: at week 8 ]
  • Weight [ Time Frame: at week 12 ]
  • Weight [ Time Frame: at week 16 ]
  • Weight [ Time Frame: at week 24 ]
  • Anti-cyclic citrullinated peptides antibodies [ Time Frame: at baseline ]
  • Anti-cyclic citrullinated peptides antibodies [ Time Frame: at week 24 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 4 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 8 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 12 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 16 ]
  • Global health by physicians (Visual Analog Scale) [ Time Frame: at week 24 ]
Complete list of historical versions of study NCT01412021 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug:

  • Unknown adverse drug reactions (especially important adverse drug reactions)
  • Incidence and conditions of occurrence of adverse reactions in the clinical setting
  • Factors that may affect the safety and effectiveness of Humira
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
- All patients who receive Humira for the treatment of Juvenile idiopathic arthritis
Arthritis, Juvenile Rheumatoid
Not Provided
Humira
those with an exposure
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
June 2018
June 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

- All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey

Exclusion Criteria:

  • Contraindications according to the Package Insert
  • Patients who have serious infections
  • Patients who have tuberculosis
  • Patients with a history of hypersensitivity to any ingredient of Humira
  • Patients who have demyelinating disease or with a history of demyelinating disease
  • Patients who have congestive cardiac failure
Sexes Eligible for Study: All
up to 99 Years   (Child, Adult, Senior)
No
Contact: AbbVie_GK Clinical_Trials_Registration_Desk +81-3-4577-1125 AbbVie_JPN_info_clingov@abbvie.com
Contact: Kaori Hozumi
Japan
 
 
NCT01412021
P12-769
Not Provided
Not Provided
Not Provided
Not Provided
AbbVie (prior sponsor, Abbott)
AbbVie (prior sponsor, Abbott)
Not Provided
Study Director: Sarina Kurimoto AbbVie GK
AbbVie
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP